Trasplante con sangre del cordón umbilical

Para el trasplante de médula ósea, los médicos de Mayo Clinic tienen experiencia en utilizar células madre de la sangre del cordón umbilical (trasplante con sangre de cordón umbilical), de la sangre periférica (trasplante de células madre de sangre periférica) y de la médula ósea (trasplante de médula ósea).

En un trasplante con sangre del cordón umbilical, las células madre se extraen de la sangre de cordón umbilical. La sangre del cordón umbilical es la sangre que queda en el cordón umbilical luego del nacimiento del bebé. La sangre del cordón umbilical puede congelarse y guardarse hasta que se la utilice en un trasplante con sangre del cordón umbilical. Si esta es una opción para ti, antes del nacimiento de tu bebé, consulta con tu médico cómo hacer para donar sangre del cordón umbilical a un banco de sangre del cordón umbilical.

La sangre del cordón umbilical tiene menos células madre disponibles que otras opciones de trasplante de médula ósea. Pero las células madre de la sangre del cordón umbilical pueden hacer crecer más células sanguíneas que aquellas recolectadas de la médula ósea. Las células de la sangre del cordón umbilical no tienen anticuerpos porque no han estado expuestas a infecciones. Esto hace que sean más tolerantes a la incompatibilidad de los tejidos entre las células del cordón y el paciente. Pueden usarse para trasplantes en pacientes que no tienen un donante totalmente compatible.

Los investigadores continúan estudiando los usos potenciales para la sangre del cordón umbilical, por ejemplo en niños con enfermedad de células falciformes.

Share your experience

Share your Mayo Clinic transplant experience with others using social media.

Aug. 21, 2018
References
  1. National Marrow Donor Program. http://bethematch.org. Accessed Feb. 26, 2015.
  2. AskMayoExpert. Hematopoietic stem cell transplant. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  3. AskMayoExpert. Graft-versus-host disease. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  4. Barbara Woodward Lips Patient Education Center. Allogeneic blood and marrow transplant (BMT). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2010.
  5. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. July 20, 2016.
  6. Lee SJ, et al. 5 year results of bmt ctn 0201: Unrelated donor bone marrow is associated with better psychological well-being and less burdensome chronic gvhd symptoms than peripheral blood. American Society of Hematology. Meeting abstract. https://ash.confex.com/ash/2015/webprogram/Paper80881.html. Accessed July 19, 2016.
  7. Adams RH (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 15, 2016.
  8. Geerdes PA (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 17, 2012.
  9. Reunited and it feels pretty good. In the Loop. July 28, 2015. http://intheloop.mayoclinic.org. Accessed July 19, 2016.
  10. Singla A, et al. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation. 2013;19:1233.
  11. Hoffman R, et al. Overview of hematopoietic stem cell transplantation. In: Hematology: Basic Principles and Practice. 6th ed. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed July 19, 2016.
  12. Dispenzieri A. POEMS syndrome: 2012 update on diagnosis, risk-stratification and management. American Journal of Hematology. 2012;87:804.
  13. Yang ZZ, et al. T-cell-mediated antitumor immunity in B-cell non-Hodgkin lymphoma: Activation, suppression and exhaustion. Leukemia and Lymphoma. 2015;56:2498.
  14. Diseases treatable by transplants. National Marrow Donor Program. https://bethematch.org/transplant-basics/how-transplants-work/diseases-treatable-by-transplants/. Accessed July 20, 2016.
  15. Majhail NS, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation. 2012;18:348.
  16. Yawn BP, et al. Management of sickle cell disease: Summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312:1033.
  17. NCCN member institutions. National Comprehensive Cancer Network. https://www.nccn.org. Accessed July 20, 2016.
  18. Cordes S, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagulation and Fibrinolysis. 2016;27:101.
  19. Colborn LK. Office of Access Management. Mayo Clinic, Rochester, Minn. Jan. 28, 2016.
  20. Gertz MA, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clinic Proceedings. 2008;83:1131.
  21. O'Suoji C, et al. Rare pediatric non-Hodgkin lymphomas: A report from Children's Oncology Group Study ANHL 04B1. Pediatric Blood Cancer. 2016;63:794.
  22. Galardy PJ, et al. Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: Therapeutic horizons. British Journal of Haematology. 2016;173:625.
  23. Slack JL, et al. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: Outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch. Biology of Blood and Marrow Transplantation. 2013;19:1167.
  24. King AA, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. American Journal of Hematology. 2015;90:1093.
  25. Mayo Clinic to grow human cells in space: Testing stroke treatment. Mayo Clinic News Network. http://newsnetwork.mayoclinic.org. Accessed July 20, 2016.
  26. Muchtar E, et al. Autologous stem cell transplant for multiple myeloma patients 70 years or older. Bone Marrow Transplant. In press.
  27. Ansell SM. Targeting immune checkpoints in lymphoma. Current Opinion in Hematology. 2015;22:337.
  28. Hashmi S, et al. Survival aster mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: Systematic review and meta-analysis. The Lancet Haematology. 2016;1:e45-52. https://www.clinicalkey.com. Accessed July 20, 2016.